Edwards Lifesciences Beats Q1 Estimates but Predicts an Ugly Q2
Like nearly every stock, Edwards Lifesciences (NYSE: EW) tanked during the coronavirus-driven stock market sell-off in late February and March. But its shares have bounced back more robustly than most stocks.
The healthcare company announced its first-quarter results after the market closed on Thursday. Here are the highlights from Edwards' Q1 update.
Image source: Getty Images.
Source Fool.com
